1. Show article details.

    US STOCKS-S&P 500 hits record high as Wall Street brushes off higher inflation data

    Reuters – 10:15 AM ET 06/10/2021

    * Meme stocks flit between gains and losses. * Boeing (BA) gains on possible UAL order. * Indexes up: Dow 0.67%, S&P 0.65%, Nasdaq 0.79% By Ambar Warrick. U.S. stocks rose on Thursday, with the S&P 500 hitting a record high, as investors doubted whether a spike in May consumer prices would spur early policy tightening by the Federal Reserve.

  2. Show article details.

    US STOCKS-Wall Street set for flat open as consumer prices jump

    Reuters – 9:05 AM ET 06/10/2021

    * Meme stocks flit between gains and losses. * Boeing (BA) gains on possible UAL order. * Futures: S&P up 0.1%, Dow up 0.2%, Nasdaq down 0.3% By Ambar Warrick. June 10 - U.S. stock indexes were set for a muted open on Thursday as a surge in consumer prices in May fanned fears of early policy tightening by the Federal Reserve, while another report showed the labor market remained under pressure.

  3. Show article details.

    Ocugen to file for full U.S. approval of COVID-19 shot instead of EUA

    Reuters – 8:04 AM ET 06/10/2021

    Ocugen Inc (OCGN) said on Thursday it would no longer pursue an emergency use authorization for its COVID-19 vaccine candidate, Covaxin, and would instead aim to file for a full U.S. approval of the shot. Ocugen (OCGN) said the decision was based on a recommendation from the U.S. Food and Drug Administration, which also requested more information and data for the full approval.

  4. Show article details.

    Ocugen to file for full U.S. approval of COVID-19 vaccine

    Reuters – 7:40 AM ET 06/10/2021

    Ocugen Inc (OCGN) on Thursday said it would file for full U.S. approval of its COVID-19 vaccine candidate, COVAXIN, without pursuing an emergency use authorization.

  5. Show article details.

    Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial

    GlobeNewswire – 7:35 AM ET 06/10/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be joining Ocugen (OCGN) as Senior Vice President, Commercial. Michael Shine is a pharmaceutical and biotechnology executive with nearly 35 years of industry experience.

  6. Show article details.

    BRIEF-Ocugen To Pursue A BLA Path In The Us For Its Covid-19 Vaccine Candidate

    Reuters – 7:34 AM ET 06/10/2021

    Ocugen Inc (OCGN): * OCUGEN TO PURSUE A BLA PATH IN THE US FOR ITS COVID-19 VACCINE CANDIDATE. * Ocugen Inc (OCGN) - TO ENGAGE WITH HEALTH CANADA TO SEEK AUTHORIZATION UNDER INTERIM ORDER FOR USE IN CANADA. * Ocugen Inc (OCGN) - WILL NO LONGER PURSUE AN EMERGENCY USE AUTHORIZATION FOR COVAXIN Source text for Eikon: Further company coverage:

  7. Show article details.

    Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate

    GlobeNewswire – 7:30 AM ET 06/10/2021

    MALVERN, Pa., June 10, 2021 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that upon recommendation from the U.S. Food and Drug Administration, it will pursue submission of a biologics license application for its COVID-19 vaccine c...

  8. Show article details.

    BRIEF-Ocugen Says Co And Bharat Entered Into That Certain First Amendment To Co-Development, Supply And Commercialization Agreement

    Reuters – 6:39 AM ET 06/07/2021

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN) - ON JUNE 1, 2021, CO AND BHARAT ENTERED INTO THAT CERTAIN FIRST AMENDMENT TO CO-DEVELOPMENT, SUPPLY AND COMMERCIALIZATION AGREEMENT. * Ocugen Inc (OCGN) - PARTIES AGREED TO EXPAND THE ORIGINAL OCUGEN TERRITORY TO INCLUDE THE UNITED STATES AND CANADA. * Ocugen Inc (OCGN) - PAID TO BHARAT $15 MILLION IMMEDIATELY UPON EXECUTION OF THE AMENDMENT.

  9. Show article details.

    BRIEF-Ocugen Expands Covaxin™ Commercialization Rights To Include Canada

    Reuters – 7:37 AM ET 06/03/2021

    Ocugen Inc (OCGN): * OCUGEN EXPANDS COVAXIN™ COMMERCIALIZATION RIGHTS TO INCLUDE CANADA. * OCUGEN (OCGN) - TO HAVE EXCLUSIVE CO-DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION RIGHTS TO COVAXIN IN CANADA, IN ADDITION TO ITS EXISTING US RIGHTS. * OCUGEN (OCGN) - WILL MAKE UPFRONT PAYMENT AND MILESTONE PAYMENT UPON FIRST COMMERCIAL SALE IN CANADA TO BHARAT BIOTECH.

  10. Show article details.

    Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada

    GlobeNewswire – 7:30 AM ET 06/03/2021

    Ocugen (OCGN), Inc., a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, and Bharat Biotech, a global leader in vaccine innovation, today announced that they have entered into an amendment to their Co-development, Supply, and Commercialization Agreement to expand Ocugen’s e...

  11. Show article details.

    BRIEF-Ocugen Says On Track To Submit EUA Application To U.S. FDA For Its COVID-19 Vaccine Candidate, Covaxin

    Reuters – 8:25 PM ET 05/26/2021

    Ocugen Inc (OCGN): * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICATION TO U.S. FDA FOR ITS COVID-19 VACCINE CANDIDATE, COVAXIN. * ACTIVE DISCUSSIONS WITH FDA RELATED TO COVAXIN INITIATED LATE LAST YEAR. * MASTER FILE SUBMITTED TO FDA ON MARCH 26, 2021; AWAITING FEEDBACK FROM FDA. * CONFIRMED ITS PLAN TO SUBMIT ITS EUA APPLICATION FOR COVAXIN TO U.S. FOOD & DRUG ADMINISTRATION IN JUNE.

  12. Show article details.

    Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™

    GlobeNewswire – 8:06 PM ET 05/26/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today confirmed its plan to submit its Emergency Use Authorization application for COVAXIN to the U.S. Food & Drug Administration in June.

  13. Show article details.

    BRIEF-Ocugen Q1 Loss Per Share $0.04

    Reuters – 7:37 AM ET 05/07/2021

    Ocugen Inc (OCGN): * Q1 LOSS PER SHARE $0.04. * CASH, EQUIVALENTS, AND RESTRICTED CASH TOTALED $44.9 MILLION AS OF MARCH 31, 2021. * CONTINUE TO MAKE PROGRESS TOWARD EMERGENCY USE AUTHORIZATION FOR COVAXIN. * ALSO CONSIDERING CLINICAL DEVELOPMENT IN SPECIAL POPULATIONS, SUCH AS CHILDREN, AS WELL AS BOOSTER DOSES FOR COVAXIN Source text for Eikon: Further company coverage:

  14. Show article details.

    Ocugen Provides Business Update and First Quarter 2021 Financial Results

    GlobeNewswire – 7:30 AM ET 05/07/2021

    Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., May 07, 2021 -- Ocugen (OCGN), Inc., a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported first quarter 2021 financial results along with a general business update.

  15. Show article details.

    BRIEF-Ocugen Presents New Preclinical OCU200 Data

    Reuters – 7:40 AM ET 05/06/2021

    Ocugen Inc (OCGN): * OCUGEN PRESENTS NEW PRECLINICAL OCU200 DATA AT THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY 2021 ANNUAL MEETING Source text for Eikon: Further company coverage:

  16. Show article details.

    Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

    GlobeNewswire – 7:30 AM ET 05/06/2021

    MALVERN, Pa., May 06, 2021 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the presentation of a pre-clinical study to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.

  17. Show article details.

    Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update

    GlobeNewswire – 4:35 PM ET 05/03/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, May 7, 2021.

  18. Show article details.

    BRIEF-Ocugen Inc Says Covaxin Effectively Neutralizes Brazil Variant Along With UK Variant And India Double Mutant Variant

    Reuters – 8:20 AM ET 05/03/2021

    Ocugen Inc (OCGN): * OCUGEN ANNOUNCES STUDIES SHOWING COVAXIN POTENTIALLY EFFECTIVE AGAINST THREE KEY VARIANTS OF SARS-COV-2. * Ocugen Inc (OCGN) - COVAXIN EFFECTIVELY NEUTRALIZES BRAZIL VARIANT ALONG WITH UK VARIANT AND INDIA DOUBLE MUTANT VARIANT Source text for Eikon: Further company coverage:

  19. Show article details.

    Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2  

    GlobeNewswire – 7:30 AM ET 05/03/2021

    MALVERN, Pa., May 03, 2021 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research-National Institute of Virology have found that COVAXIN demonstrated potential effective...

  20. Show article details.

    Analysis: New meme stocks swing as shorts and retail investors face off again

    Reuters – 1:27 PM ET 04/30/2021

    Recent volatility in a handful of so-called meme stocks is putting the spotlight back on the tussle between individual investors and short sellers, months after a wild ride in GameStop (GME) captivated Wall Street's attention.

Page:

Today's and Upcoming Events

  • Aug
    12

    OCGN to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    07

    OCGN announced Q1 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.